RxDoctor Payments Data

Bosheng Qiu, MD

Internal Medicine · Alhambra, CANPI 1417096363

Payments from drug & device makers

$286,025in general payments, 2019–2025

Across 2,553 payments — averaging $112.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$98K
  • Amgen$46K
  • Amarin Pharma, Inc.$23K
  • Boehringer Ingelheim$23K
  • Gilead$17K
  • Ironwood Pharmaceuticals, Inc$16K
  • plus $64K from 54 others

What the payments were for

  • Consulting fees$4,0201%
  • Speaking & faculty fees$204,65872%
  • Travel & lodging$8,1613%
  • Food & beverage$68,85524%
  • Education$3310%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)401$97,825
Amgen266$45,846
Amarin Pharma, Inc.67$22,640
Boehringer Ingelheim97$22,619
Gilead53$16,678
Ironwood Pharmaceuticals, Inc85$16,176
Lilly USA, LLC63$16,020
AstraZeneca219$8,528
Corium, LLC11$3,459
GSK148$3,224
Merck82$2,723
Mylan Specialty L.p.8$2,557
Novo Nordisk65$1,951
Johnson & Johnson58$1,747
Esperion Therapeutics, Inc.45$1,746
Bayer53$1,598
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC66$1,312
Novartis43$1,276
Mannkind Corporation67$1,232
Pfizer59$1,203
Avanir Pharmaceuticals, Inc.41$893
Ardelyx, Inc.28$815
Phathom Pharmaceuticals, Inc.21$790
Almatica Pharma LLC37$776
Astellas Pharma US Inc25$736
Redhill Biopharma Inc.58$700
Madrigal Pharmaceuticals11$699
Otsuka America Pharmaceutical, Inc.17$682
Takeda Pharmaceuticals U.S.A., Inc.34$635
Xeris Pharmaceuticals, Inc.30$624
Abbott16$622
Kvk-tech, Inc.17$537
Oyster Point Pharma, Inc.21$528
Kowa Pharmaceuticals America, Inc.17$507
Nestle Healthcare Nutrition Inc.20$433
Biohaven Pharmaceutical Holding Company Ltd.18$425
Radius Health, Inc.8$424
E.r. Squibb & Sons, L.L.C.22$395
Dexcom, Inc.11$379
Regeneron Healthcare Solutions, Inc.7$369
Biohaven Pharmaceuticals, Inc.10$345
Lexicon Pharmaceuticals, Inc.10$327
Teva Pharmaceuticals USA, Inc.15$324
Vivus LLC14$294
Sun Pharmaceutical Industries Inc.14$286
Alkermes, Inc.12$256
Sanofi-aventis U.S. LLC2$232
Portola Pharmaceuticals, LLC2$221
Aimmune Therapeutics, Inc.6$151
Hikma Pharmaceuticals USA7$141
Kyowa Kirin, Inc.1$122
Scilex Pharmaceuticals Inc.6$117
Genentech USA, Inc.6$105
Acorda Therapeutics, Inc5$91
Sanofi1$90
Eisai Inc.4$86
Ionis Pharmaceuticals, Inc.3$75
Sumitomo Pharma America, Inc.3$65
Arbor Pharmaceuticals, Inc.3$57
Adamas Pharmaceuticals, Inc.3$56

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$286,025 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$620,670
Medicare patients
480
Services billed
8,020

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin1,167$677,365
CreonLipase/Protease/Amylase280$458,465
RybelsusSemaglutide379$385,458
VascepaIcosapent Ethyl832$314,049
LinzessLinaclotide521$268,840
Icosapent Ethyl1,298$259,148
Cyclosporine557$228,299
KerendiaFinerenone327$208,811
RestasisCyclosporine277$186,892
EliquisApixaban384$146,600
AfrezzaInsulin Regular, Human74$94,089
TradjentaLinagliptin193$87,206
JanuviaSitagliptin Phosphate166$83,990
Breztri AerosphereBudesonide/Glycopyr/Formoterol118$81,738
Memantine Hcl ErMemantine Hcl855$76,863

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess, Restasis$97,825$914,1981,078 claims
Boehringer IngelheimJardiance, Tradjenta, Jentadueto$22,619$782,2711,401 claims
Novo NordiskRybelsus, Ozempic$1,951$413,304408 claims
BayerKerendia$1,598$208,811327 claims
MerckJanuvia, Janumet$2,723$150,273277 claims
PfizerEliquis$1,203$146,600384 claims
AstraZenecaBreztri Aerosphere, Brilinta, Lokelma$8,528$140,728218 claims
Mannkind CorporationAfrezza$1,232$94,08974 claims
Johnson & JohnsonXarelto$1,747$76,308131 claims
GSKTrelegy Ellipta$3,224$56,33289 claims
GileadVemlidy$16,678$49,91736 claims
Esperion Therapeutics, Inc.Nexletol$1,746$46,473115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Alhambra

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →